Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment
Naim Alkhouri, Eric Lawitz, Mazen Noureddin – 28 March 2019 – Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide, and its aggressive form of nonalcoholic steatohepatitis (NASH) is becoming a leading cause for end‐stage liver disease and liver transplantation in the United States. In patients with NASH, the presence of advanced fibrosis is considered the most important prognostic factor in predicting liver‐related morbidity and mortality.